Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Litigation Details for Onyx Pharmaceuticals, Inc. v. Bayer Corporation (N.D. Cal. 2009)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Onyx Pharmaceuticals, Inc. v. Bayer Corporation (N.D. Cal. 2009)

Docket   Start Trial Date Filed 2009-05-15
Court District Court, N.D. California Date Terminated 2011-10-17
Cause 28:1332 Diversity-Other Contract Assigned To Edward Milton Chen
Jury Demand Both Referred To
Patents 7,351,834
Attorneys Alison Margaret Tucher; Amy Christine Dachtler; Bradley Allen Waugh; Brian Charles Swanson; Daniel Jedediah Knauss; Georgia N. Alexakis ,; J. Scott McBride; James Breckinridge Heaton , III; Jason Lloyd Peltz; Jeffrey Gutkin; Lawrence R. Katzin; Mark Leslie Levine; Martin S. Schenker; Michelle S. Rhyu; Philip Scott Beck; Thomas J. Friel , Jr.
Firms Bartlit Beck; Bartlit Beck Herman Palenchar & Scott; Bartlit Beck Herman Palenchar & Scott LLP; Bartlit Beck Herman Palenchar and Scott LLP; Bartlit Beck Herman Palenchar Scott; Cooley Godward Kronish; Cooley LLP; King & Spalding LLP; Morrison & Foerster LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Onyx Pharmaceuticals, Inc. v. Bayer Corporation
The small molecule drugs covered by the patent cited in this case are   Start Trial and   Start Trial .

Details for Onyx Pharmaceuticals, Inc. v. Bayer Corporation (N.D. Cal. 2009)

Date Filed Document No. Description Snippet Link To Document
2011-04-19 136 Objection Deposition Exhibit 190, U.S. Patent No. 7,351,834, issue date April 1,2008. …Onyx Deposition Exhibit 74, International Patent Publication number WO 2005/009961, dated February…copy of Bayer Deposition 2 Exhibit 200, U.S. Patent Application Publication number US 2005/0038080, External link to document
2010-06-22 54 Stipulation and Order 10 No. 7,351,834 claims the chemical structures of sorafenib and its halogenated…compound. The patent that ultimately issued from this application as United States Patent … 2 surreptitiously filing patent applications and initiating clinical trials. …claimed in an Onyx or Bayer 15 patent and (b) that were ‚Äúsynthesized, identified or discovered…13 25. Article 20.2 addresses patent disclosures, obligating a party to disclose to External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.